from Reuters: Business News https://ift.tt/2Stqvkj
Thursday, December 26, 2019
Astellas ramps up M&A, buys U.S. biotech Xyphos for as much as $665 million
Astellas Pharma Inc has bought U.S.-based Xyphos Biosciences Inc to expand its immuno-oncology business, a deal worth up to $665 million including potential development milestones and its second acquisition announced this month.
from Reuters: Business News https://ift.tt/2Stqvkj
from Reuters: Business News https://ift.tt/2Stqvkj
Related Posts:
Recent market "jolt" will be first of many as easy money era ends, says BIS- 5 Financial Lessons Baby Boomers Can Teach Us
- 5 Things That Really Matter When Investing in Marijuana Stocks
- Qatar considering increasing its stake in Deutsche Bank: Handelsblatt
- Regulators need joined up thinking to spot derivatives risks: BIS
0 comments:
Post a Comment